Royalty Report: Drugs, Cancer, ribonucleic acid – Collection: 299237


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Cancer
  • ribonucleic acid
  • Therapeutic
  • Diabetes Treatment
  • Antibody

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 299237

License Grant
Licensor hereby grants to Licensee
— a non-exclusive license under the Patent Rights, to make, have made, use, and/or sell Licensed Products for human and non-human applications;
— the right under the Patent Rights to grant to an Affiliate a sublicense; and,
— the right under the Patent Rights to grant to Product Development Partner(s) a single sublicense for each specific application of Licensed Product.
License Property
The patent properties cover the T7 technology, such as, Cloning and Expression of the Gene for Bacteriophage TI RNA Polymerase.

The Designated Product shall mean a protein or other product produced through use of the T7 technology.

SGN-10 is a single-chain immunotoxin that binds to cancer cells and kills them by delivering a protein toxin inside the cell. SGN-10 is composed of the receptor binding portion of the BR96 monoclonal antibody and a truncated portion of a protein toxin called  Pseudomonas    exotoxin A. SGN-10 is currently in two phase I clinical trials.

The term 'Patent Rights' shall mean
    1.  United States Patent No. 4,952,496 entitled 'Cloning and Expression of the Gene for Bacteriophage T7 RNA Polymerase', and any reissue thereof;

    2.  U.S. Patent No. 5,693,489 entitled 'Cloning and Expression of the Gene for Bacteriophage T7 RNA Polymerase', and any reissue thereof;

Field of Use
The field of use is to produce anti-cancer products.

IPSCIO Record ID: 243427

License Grant
The University grants to the Licensee a non-exclusive, worldwide, royalty-bearing license, with the right to sublicense, under its commercial rights in the Patent Rights and Biological Materials to develop, make, have made, use, and sell Licensed Products in the Field.  Licensee shall have the right to grant sublicenses.
License Property
The patents are for RNA Sequence-Specific Mediators of RNA Interference.

Licensed Product means any product that cannot be developed, manufactured, used, or sold without infringing one or more claims under the Patent Rights, or, using or incorporating some portion of one or more Biological Materials.

Biological Materials means the tangible biological materials described in the patents, as well as tangible materials that are routinely produced through use of the original materials, including, for example, any progeny derived from a cell line, monoclonal antibodies produced by hybridoma cells, DNA or RNA replicated from isolated DNA or RNA, recombinant proteins produced through use of isolated DNA or RNA, and substances routinely purified from a source material included in the original materials.

UMMC 01-36 “RNA Sequence-Specific Mediators of RNA Interference” Inventors David P. Bartel, Philip A. Sharp, Thomas Tuschl, and Philip D. Zamore
I. United States Patents and Application
USSN 60/265232 entitled “RNA Sequence-Specific Mediators of RNA Interference”

USSN 09/821832 entitled “RNA Sequence-Specific Mediators of RNA Interference”
PCT/US01/10188 entitle “RNA Sequence-Specific Mediators of RNA Interference”

Field of Use
The field of use is therapeutics limited to the narrowed fields of other Medical School license agreements; specifically, using RNAi to inhibit HCMV Immediate Early (IE) gene expression in Retinitis applications, using RNAi to inhibit mutant SOD 1 gene expression in Amytrophic Lateral Sclerosis (ALS) applications, and using RNAi to inhibit gene targets implicated in Type II Diabetes and Obesity under the rights of Medical School in any patent rights claiming those inventions.

IPSCIO Record ID: 166843

License Grant
Licensee grants to German Licensor an exclusive license to make, have made, use, import, export, distribute for sale and to offer to sell the Licensed Products in all territories of the world (the Territory) the Technology within the Field (collectively referred to as the License).
License Property
Technology shall mean that technical information owned by or licensed to Licensee related to the combination of a Pseudomonas exotoxin, or a derivative thereof (hereinafter referred to as PE), with erbB2 ligand or portion(s) thereof capable of targeting the erbB2 antigen.

Licensed Product(s) shall mean compounds and methods of therapy utilizing the Technology within the Field.

Specialties means finished pharmaceutical preparations in dosage form which contain a Licensed Product as an active ingredient.

License L-318-91, Oncologix, Inc./Medical Oncology, Inc. erbB-2 License

U.S. Patent Number 5,458,878 (USSN 07/522,562 (CIP of 07/459,635)), filed May 14, 1990, issued October 17, 1995, entitled  'Target-Specific, Cytotoxic, Recombinant Pseudomonas Exotoxin,' Pastan et al.

Background Licensed Patent Rights

U.S. Patent Number 4,892,827 (USSN 06/911,227), filed September 24, 1986, entitled  'Recombinant Pseudomonas Exotoxins Construction of an Active Immunotoxin with Low Side Effects'

U.S. Patent Application Number 06/836,414, filed March 5, 1986, entitled 'Human Gene Related to but Distinct From EGF Receptor Gene,' Richter et al.

L-211-84/0, Oncologix, Inc./Medical Oncology, Inc. EGF License

Field of Use
This agreement pertains to the drug industry relating to cancer therapy.

IPSCIO Record ID: 256278

License Grant
On the Effective Date the Parties have terminated a certain Collaboration Agreement, and with this agreement, the Parties desire to reallocate the rights and responsibilities of the Parties with respect to further research and development of the GM-CSF Target.

Licensor grants to Licensee of Germany an exclusive, worldwide, license under the Licensor Licensed Technology to Exploit Licensed Products.

Licensor grants a worldwide, non-exclusive, perpetual, irrevocable and non-terminable license under the Collaboration Patents, as defined in the Collaboration Agreement, with the right to grant and authorize the grant of sublicenses, to Exploit Licensed Products.

License Property
BiTE Product means any composition or formulation consisting of or comprising a bi-specific Single Chain Antibody expressed as a single polypeptide chain, binding to T-cells.

GM-CSF Target means the whole or part of the human granulocyte macrophage-colony stimulating factor identified by the SWISS-PROT entry name CSF2 HUMAN and accession number P0414 l.

Single-Chain Antibodies
Antibodies are proteins produced by the body's immune system in response to the presence of antigens, such as bacteria, viruses or other disease causing agents. Antibodies of identical molecular structure that bind to a specific target are called monoclonal antibodies. Single-chain antibodies are genetically engineered antibodies that incorporate only the antigen binding domains of an antibody. Thus, SCAs have the binding specificity and affinity of monoclonal antibodies; however, in their native form they are only one-fifth to one-sixth the size of a monoclonal. The small size of SCAs typically gives them shorter half-lives than monoclonal antibodies, making them better suited for use in acute indications or in other indications where the large size of a monoclonal antibody would inhibit the compound from reaching the area of potential therapeutic activity. In addition, SCAs are a well-established discovery format-of-choice in generating antibodies from phage or yeast display libraries.

Field of Use
The field for Patent 5,223,409 is solely in the field of manufacture, use or sale of Single Chain Antibodies.

The field of use for this agreement otherwise is limited to not include the right to exploit the Products for Radioimmunoguided Surgery(TM), Reagents and kits in the research market for production and cloning of genes encoding Single Chain Antibodies and their fusions in a filamentous bacteriophage-derived vector system, and for expression and screening of Single Chain Antibodies fused with the minor coat protein or attachment or adsorption protein of filamentous bacteriophage, and, Single Chain Antibodies fused with, or for the assay or purification of, Tumor Necrosis l Factor alpha (TNF-a.) or Lymphotoxin.

Products for Radioimmunoguided SurgeryTM (RIGS'), in which a radiolabelled Single Chain Antibody is administered to a cancer patient; time elapses for preferential concentration of the radiolabelled Single Chain Antibody in neoplastic tissue and decrease of background radioactivity in the patient; and such preferentially concentrated radiolabelled Single Chain Antibody is detected within a surgical operative field by a detector probe placed in juxtaposition with tissue suspected of containing said radiolabelled Single Chain Antibody.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.